Mitochondrial Dysfunction Articles & Analysis
7 news found
NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study, supporting its precision medicine approach to the diagnosis and treatment of autism spectrum disorder (ASD) at the National TACA Autism Conference. CAMP is the largest clinical study ...
Creative Biogene unveiled a rich portfolio of efficient cell apoptosis assay kits targeted to detect mitochondrial permeability transition pore (MPTP) as well as mitochondrial membrane potential (MMP) to assist researchers in mitochondrial studies. Mitochondrial dysfunction has been linked to a variety of market therapeutics and pathological diseases. Therefore, studying or maintaining ...
New York, United States—June 28, 2022—Creative Biogene offers one-stop mitochondria-focused testing services for the evaluation of a variety of cardiac diseases associated with mitochondrial dysfunction, which can provide insights and potential treatments for mitochondrial disorders in the preclinical stages. With its ready-to-use models and assays for cardiac diseases, customers can accurately ...
New York, United States—April 21, 2022—Defects in mitochondrial function have long been suspected of contributing to the development of cancer. In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through in-depth mitochondrial function testing ...
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the Company has been issued Indian Patent IN201617027528 specific to its global patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their ...
New study results for Tikomed’s platform lead drug candidate ILB® in the treatment of patients with amyotrophic lateral sclerosis (ALS), have now been published in the Journal of Personalized Medicine. The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the ...
Lawrence Berkeley National Laboratory has been awarded $12.8 million in American Recovery and Reinvestment Act funding by the National Institutes of Health (NIH) for research into cancer, neurodegenerative diseases, radioactive decontamination and a variety of other health conditions. The grants bring Berkeley Lab’s total Recovery Act funding to more than $240 million in areas covering energy, ...